Bacterial degradation of the MYC oncogene -- a new cancer treatment strategy?

February 12, 2021

Scientists at Lund University have discovered how E. coli bacteria target and degrade the well-known oncogene MYC, which is involved in many forms of cancer. The study is now published in Nature Biotechnology.

Cancer cells grow too fast, outcompete normal cells and spread to distant sites, where they cause metastases. Understanding what makes cancer cells so efficient and threatening is critically important and stopping them has always been the goal of cancer research. Early studies identified so-called ''oncogenes''; genes that that normally control cell growth but when mutated may be responsible for the creation of cancer cells and explain their competitive advantage.

The pleiotropic transcription factor MYC has been named ''the quintessential oncogene'' and is hyperactive in the majority of human cancers. Targeting MYC is therefore highly desirable. Still, finding c-MYC inhibitors for therapeutic use has been problematic and MYC itself has long been viewed as "undruggable".

Researchers at Lund University have made the surprising discovery that uropathogenic E. coli deplete c-MYC protein from infected cells and tissues as a result of accelerated c-MYC protein degradation and attenuated MYC expression.

The discovery was made after observing that children with acute pyelonephritis have decreased MYC expression. By screening molecules released by the bacteria, Lon protease was identified as the main effector of MYC degradation, with selectivity for MYC. The bacterial strategy was then translated into cancer therapy, showing prominent effects of Lon treatment in two different cancer models. Potent treatment effects on tumor growth and increased survival support the therapeutic potential of this molecule.. Surprisingly, the Lon protease was shown to mainly affect cells where MYC is overactive, suggesting limited toxicity. These findings have now been published in Nature Biotechnology

''The next step is to understand this "magical molecule" in more detail and to develop the project for future clinical trials''

Lund University

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to